Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
LKB1 deficiency renders non-small-cell lung cancer cells sensitive to ERK inhibitors.: ERK inhibitors in LKB1 mutated NSCLC.
|
31634668 |
2020 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
KRAS G12D and STK11 mutations confer poor prognoses for patients with KRAS-mutant NSCLC.
|
31200821 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
LCNEC can be subdivided in two main subtypes: the first harboring TP53/RB1 mutations (small cell lung carcinoma (SCLC)-like), the second with mutations in TP53 and STK11/KEAP1 (non-small cell lung carcinoma (NSCLC)-like).
|
31751303 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
As ID1 expression is up-regulated and confers poor prognosis in LKB1-deficient NSCLC, our results suggest that small molecules that inhibit CRTC2 and ID1 activity may provide therapeutic benefit to individuals with NSCLC.
|
31355336 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
SIGNIFICANCE: The tumor suppressor <i>LKB1/STK11</i> encodes a serine/threonine kinase frequently inactivated in NSCLC.
|
31350328 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Hence, our findings support that enhanced E-cadherin by GA cooperates LKB1, leading to up-regulation of p-AMPK, and thus blocking of mTOR signaling pathway, which provide theoretical foundation for utilization of GA as a potential targeted drug against NSCLC harboring wild-type LKB1.
|
31513784 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In vitro and in vivo experiments showed the synergistic effect of mTOR inhibition and PI3K inhibition in LKB1-mutant NSCLC cell lines.
|
30825612 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
NKT can activate AMP-activated protein kinase (AMPK) in liver and muscle cells, however, little is known about the role of NKT in cancer, particularly its role in NSCLC with high rates of liver kinase B1 (LKB1) and KRAS mutations.
|
31280139 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
LKB1/AMPK can be involved in the cell metabolism of NSCLC and miR-451 is negatively correlated with LKB1/AMPK.
|
31389598 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In addition, metformin and tenovin-6 synergistically suppressed SIRT1 expression in NSCLC cells regardless of LKB1 status.
|
30710424 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Loss of LKB1-AMPK signaling confers sensitivity to energy depletion and to redox homeostasis impairment and has been associated with an improved outcome in advanced NSCLC patients treated with chemotherapy.
|
31781355 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mutations in <i>STK11</i> (LKB1) are a major cause of primary resistance to immunotherapy in non-small cell lung cancer.
|
30626603 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Twenty-three single nucleotide polymorphisms (SNPs) in the LKB1 pathway were investigated in 782 patients with NSCLC who underwent curative surgery.
|
30585697 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
An expression quantitative trait locus variant for LKB1 gene predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer.
|
30553476 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here we investigated the role of INSL4, a member of the insulin/IGF/relaxin superfamily, in LKB1-inactivated NSCLCs.
|
30423141 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
|
30068711 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In the case of LCNECs, which present with a high mutation burden, two major molecular subtypes have been identified: one with biallelic inactivation of tumor protein p53 gene (TP53) and retinoblastoma gene (RB1), a hallmark of SCLC; and the other one with biallelic inactivation of TP53 and serine/threonine kinase 11 gene (STK11)/kelch like ECH associated protein 1 gene (KEAP1), genes that are frequently mutated in NSCLC.
|
29454048 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The impact of <i>STK11/LKB1</i> alterations on clinical outcomes with PD-1/PD-L1 inhibitors extended to PD-L1-positive non-small cell lung cancer.
|
29773717 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
About half of NSCLCs with activating KRAS lesions also have deletions or inactivating mutations in the serine/threonine kinase 11 (LKB1) gene.
|
30514331 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Next-generation sequencing (NGS) for <i>TP53, RB1, STK11,</i> and <i>KEAP1</i> genes, as well as IHC for RB1 and P16 was performed on 79 and 109 cases, respectively, and correlated with overall survival (OS) and progression-free survival (PFS), stratifying for non-small cell lung cancer type chemotherapy including platinum + gemcitabine or taxanes (NSCLC-GEM/TAX) and platinum-etoposide (SCLC-PE).<b>Results:</b><i>RB1</i> mutation and protein loss were detected in 47% (<i>n</i> = 37) and 72% (<i>n</i> = 78) of the cases, respectively.
|
29066508 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study lays the foundations for combining metformin with standard platinum-based chemotherapy in the treatment of KRAS/LKB1 co-mutated NSCLC.
|
30149143 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Pathologically, the amplification or activation of AURKA-induced impairment of the LKB1/AMPK signaling pathway contributes to NSCLC initiation and progression, highlighting AURKA as a potential therapeutic target for combatting hyperactive AURKA-driven NSCLCs.
|
28967900 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The results showed that inhibiting LKB1 or MARK1 in NSCLC increases the collagen fiber alignment and captures outward alignment vectors from the tumor spheroid, corresponding to high invasiveness of LKB1 mutant cancer cells.
|
28045069 |
2017 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Together, our data implicate LKB1 as a major regulator of adaptive metabolic reprogramming and suggest synergistic pharmacological strategies for mitigating LKB1-deficient NSCLC tumor growth.
|
28034771 |
2017 |
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Transcription of CPS1 is suppressed by LKB1 through AMPK, and CPS1 expression correlates inversely with LKB1 in human NSCLC.
|
28538732 |
2017 |